Regeneron Pharmaceuticals said on Monday it seeks to defend against U.S. Department of Justice's complaint that alleged the company misreported the average sales price of its macular degeneration drug Eylea.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,